PolTREG
Regulatory T-cell therapy · Type 1 diabetes, MS, ALS
Overview
World-leading clinical-stage developer of regulatory T-cell (Treg) therapies that retrain the immune system to stop attacking the body — lead programs in early type-1 diabetes and multiple sclerosis.
What they do
PolTREG is a clinical-stage Polish biotech pioneering regulatory T-cell (Treg) therapies that aim to retrain the immune system to stop attacking the body, addressing autoimmune and neuroinflammatory diseases. Its lead indications are type 1 diabetes and multiple sclerosis, with longer-term ambitions in other autoimmune conditions. The company is GPW-listed and built on academic Treg expertise from Gdansk.
Lead program & status
Its lead autologous Treg product, referenced as PTG-007, has the longest clinical track record. At EASD 2024, PolTREG reported that some early-onset type 1 diabetes patients treated with its Treg therapy remained in clinical remission for up to 12 years. In October 2024 it launched a placebo-controlled Phase 2 trial in presymptomatic type 1 diabetes (planned ~150 patients aged 6-16 at high genetic risk) after EMA approval, and it initiated Phase 2 work in multiple sclerosis (RRMS/PPMS). It is also advancing next-generation engineered Tregs, including CAR-Treg programs, in preclinical development.
Why it matters
PolTREG is among the world's most advanced Treg-therapy developers, offering a potentially disease-modifying approach where current autoimmune treatments only manage symptoms.
FAQ
- What is a Treg therapy?
- Regulatory T-cell (Treg) therapy uses immune cells that dampen harmful immune responses, aiming to stop the body from attacking its own tissues in autoimmune and neuroinflammatory disease.
- What is PolTREG's lead program?
- Its autologous Treg therapy (referenced as PTG-007) for type 1 diabetes, including a Phase 2 trial in presymptomatic patients launched in 2024, alongside a Phase 2 program in multiple sclerosis.
- What did PolTREG report at EASD 2024?
- It reported long-term safety and efficacy, with some early type 1 diabetes patients reportedly remaining in clinical remission for up to 12 years after treatment.
Technology
PolTREG works in Regulatory T-cell (Treg) Therapy — Retraining the immune system to stand down instead of attack.
Read the Regulatory T-cell (Treg) Therapy brief →Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.